Navigation Links
InCode BioPharmaceutics Appoints New President and CEO
Date:11/20/2008

SAN FRANCISCO, Nov. 20 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging company in complement depletion, announced that it has appointed Kevin L. Stark, Ph.D. as President and Chief Executive Officer, effective immediately. Dr. Stark has more than 19 years experience as a biopharmaceutical researcher and executive, most recently as an Executive Director at Amgen, and Chief Operating Officer at iZumi Bio, Inc. His latest responsibilities included strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.

"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."

Dr. Stark received a Ph.D. in Pharmacology from the University of Washington, and a B.S. in Zoology from Colorado State University.

InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.

"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.

In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.

About InCode

InCode's novel approach is focused on the selective interruption of the complement cascade. Activation of the complement cascade has been implicated in the pathogenesis of many inflammatory diseases, including rheumatoid arthritis, asthma, ischemia-reperfusion injury and age-related macular degeneration. Importantly, there is increased appreciation for the role of complement in certain types of cancer.

    For more information, contact:
    info@incodebp.com
   http://www.incodebp.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
2. GeneNews appoints Canadian Colorectal Cancer Advisory Board
3. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
4. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
5. Accumetrics Appoints John J. Young, MD Chief Medical Officer
6. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
7. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. NutraCea Appoints New Chief Financial Officer
10. Cardiac Science Appoints Dave Marver as Chief Operating Officer
11. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market ... 2013. The market is expected to grow at a five-year compound ... from $50.6 billion in 2015 to $96.6 billion in 2020. ... (2015 to 2020) are discussed. As well, new products approved in ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):